Department of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.
Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford University, Stanford, CA, USA.
Int Rev Psychiatry. 2022 Nov-Dec;34(7-8):715-726. doi: 10.1080/09540261.2022.2132137. Epub 2022 Oct 18.
Depression, either bipolar or unipolar, is a highly prevalent and disabling condition. Even though several treatment options exist for depressed patients, a significant portion of individuals receiving conventional pharmacotherapy fails to achieve and sustain remission. For this reason, there is a strong need for effective alternatives to pharmacotherapy. In this respect, non-invasive brain stimulation (NIBS), including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), have been increasingly investigated in the last two decade as promising treatment strategies for major depression and treatment-resistant depression (TRD). Indeed, due to their safety and tolerability and to the growing evidence on their efficacy, NIBS has been included in international treatment guidelines, having become part of the standard clinical practice. Even though several clinical trials involving NIBS in patients with major depression and TRD have been conducted, literature in specific areas is still marked by some inconsistencies, due to small sample-sizes, lack of multicentre-studies and to the difficulty in comparing different treatment modalities and stimulation protocols. In light of the above, we sought to provide a brief, updated compendium of the latest innovative acquisition for the use of NIBS in the treatment of depression, either unipolar or bipolar, as well as TRD with a specific focus on innovative set-up, devices, target areas, and parameters that may affect the outcome.
抑郁,无论是双相还是单相,都是一种高发且致残的疾病。尽管有多种治疗选择可供抑郁患者使用,但相当一部分接受常规药物治疗的患者无法实现并维持缓解。出于这个原因,人们强烈需要药物治疗以外的有效替代方案。在这方面,非侵入性脑刺激(NIBS),包括经颅磁刺激(TMS)和经颅直流电刺激(tDCS),在过去二十年中作为治疗重度抑郁症和治疗抵抗性抑郁症(TRD)的有前途的治疗策略越来越受到关注。事实上,由于其安全性和耐受性,以及其疗效的不断增加的证据,NIBS 已被纳入国际治疗指南,成为标准临床实践的一部分。尽管已经进行了几项涉及重度抑郁症和 TRD 患者的 NIBS 临床试验,但由于样本量小、缺乏多中心研究以及难以比较不同的治疗方式和刺激方案,特定领域的文献仍然存在一些不一致之处。有鉴于此,我们旨在提供一份关于使用 NIBS 治疗抑郁症(无论是单相还是双相)和 TRD 的最新创新成果的简要、更新的综合报告,特别关注创新设置、设备、目标区域和可能影响结果的参数。